ICD Research's 'Novo Nordisk A/S: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.

ICD Research's 'Novo Nordisk A/S: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Scope

Examines and identifies key information and issues about 'Novo Nordisk A/S' for business intelligence requirements.

Novo Nordisk A/S (Novo Nordisk) is a leading provider of diabetic care products across the world. The company also maintains leading positions within growth hormone therapy, haemophilia care, and hormone replacement therapy. Novo Nordisk discovers, develops, manufactures, and markets pharmaceutical products and services for patients, medical professionals and society. The company classifies its operations under two segments - Diabetes care and Biopharmaceuticals. It has a network of subsidiaries, affiliates, and offices in 74 countries, and markets its products in over 180 countries across the world. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

1 BUSINESS ANALYSIS

1.1 Company Overview
1.2 Business Description
1.3 Major Products and Services